See more : BRAIN Biotech AG (BNN.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Sana Biotechnology, Inc. (SANA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sana Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- VA Tech Wabag Limited (WABAG.BO) Income Statement Analysis – Financial Results
- Ruentex Materials Co.,Ltd. (8463.TW) Income Statement Analysis – Financial Results
- Électricite de Strasbourg Société Anonyme (ELEC.PA) Income Statement Analysis – Financial Results
- Fathom Digital Manufacturing Corporation (FATH) Income Statement Analysis – Financial Results
- Jiangsu Yunyi Electric Co.,Ltd. (300304.SZ) Income Statement Analysis – Financial Results
Sana Biotechnology, Inc. (SANA)
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| Gross Profit | -30.87M | -27.73M | -17.91M | -10.17M | -3.92M | -1.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.64M | 201.00M | 306.50M | 257.88M | 119.38M | 4.01M |
| General & Administrative | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 8.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.21M |
| SG&A | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| Other Expenses | 0.00 | -674.00K | 305.00K | 97.00K | -29.00K | 0.00 |
| Operating Expenses | 294.94M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Cost & Expenses | 325.81M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Interest Income | 9.94M | 3.76M | 676.00K | 747.00K | 2.86M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| EBITDA | -252.39M | -256.94M | -356.91M | -287.03M | -138.90M | -13.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -326.90M | -272.56M | -356.91M | -286.15M | -141.15M | -8.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 43.65M | 3.09M | 981.00K | 844.00K | 2.83M | -5.03M |
| Income Before Tax | -283.26M | -269.48M | -355.93M | -285.31M | -138.33M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.09M | -11.75M | -6.67M | -7.55M | 0.00 |
| Net Income | -283.26M | -266.39M | -344.18M | -278.64M | -130.78M | -13.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| EPS Diluted | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| Weighted Avg Shares Out | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Weighted Avg Shares Out (Dil) | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SANA
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
Sana Biotechnology, Inc. Being Investigated on Behalf of Sana Biotechnology, Inc. Investors. Contact Levi & Korsinsky For Details.
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
Sana Biotechnology to Present at September 2024 Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports